Mark Leonard Singleton - 15 Mar 2024 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
SVP & CFO
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
4
Filing time
22 Mar 2024, 17:22:04 UTC
Previous filing
22 Jun 2023
Next filing
25 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Award $0 +80,610 $0.000000 80,610 15 Mar 2024 Class A Common Stock 80,610 Direct F1, F2
transaction BVS Restricted Stock Units Award $0 +42,202 $0.000000 42,202 15 Mar 2024 Class A Common Stock 42,202 Direct F1, F3
transaction BVS Stock Option (Right to Buy) Award $0 +181,980 $0.000000 181,980 15 Mar 2024 Class A Common Stock 181,980 $5.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
F3 The RSUs shall vest on June 15, 2024, subject to the Reporting Person continuing in service through the applicable vesting date.